Structure Therapeutics (NASDAQ:GPCR) Trading Up 7.5% - What's Next?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Get Free Report) traded up 7.5% during mid-day trading on Wednesday . The company traded as high as $17.16 and last traded at $16.97. 584,887 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 850,763 shares. The stock had previously closed at $15.79.

Wall Street Analyst Weigh In

Several research firms have weighed in on GPCR. William Blair began coverage on Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating on the stock. HC Wainwright reiterated a "buy" rating and issued a $80.00 price target on shares of Structure Therapeutics in a report on Thursday, December 19th. JMP Securities reissued a "market outperform" rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $50.00 price objective on the stock. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $81.29.

Structure Therapeutics Trading Down 5.4 %

The firm's fifty day moving average price is $23.03 and its two-hundred day moving average price is $30.34. The stock has a market capitalization of $820.58 million, a PE ratio of -19.34 and a beta of -1.35.

Remove Ads

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.01. As a group, sell-side analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. GAMMA Investing LLC raised its stake in shares of Structure Therapeutics by 663.8% during the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock worth $152,000 after buying an additional 7,627 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Structure Therapeutics in the 4th quarter worth $3,091,000. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics during the fourth quarter worth $34,000. Woodline Partners LP lifted its holdings in Structure Therapeutics by 0.7% during the fourth quarter. Woodline Partners LP now owns 333,901 shares of the company's stock valued at $9,055,000 after purchasing an additional 2,328 shares in the last quarter. Finally, Vestal Point Capital LP grew its position in shares of Structure Therapeutics by 50.0% in the fourth quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after purchasing an additional 575,000 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.